X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs PANACEA BIOTECH - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA PANACEA BIOTECH SUN PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 25.1 172.3 14.6% View Chart
P/BV x 3.7 3.8 95.7% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 SUN PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
PANACEA BIOTECH
Mar-14
SUN PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs842149 566.3%   
Low Rs57282 695.5%   
Sales per share (Unadj.) Rs131.684.1 156.4%  
Earnings per share (Unadj.) Rs32.7-18.3 -178.6%  
Cash flow per share (Unadj.) Rs38.0-6.7 -566.9%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs152.783.7 182.4%  
Shares outstanding (eoy) m2,399.2661.25 3,917.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.41.4 391.5%   
Avg P/E ratio x21.6-6.3 -342.8%  
P/CF ratio (eoy) x18.6-17.2 -108.0%  
Price / Book Value ratio x4.61.4 335.7%  
Dividend payout %10.70-   
Avg Mkt Cap Rs m1,696,8777,074 23,986.2%   
No. of employees `00017.52.8 636.9%   
Total wages/salary Rs m49,0231,449 3,382.8%   
Avg. sales/employee Rs Th18,028.31,874.1 962.0%   
Avg. wages/employee Rs Th2,798.8527.0 531.1%   
Avg. net profit/employee Rs Th4,479.5-407.7 -1,098.6%   
INCOME DATA
Net Sales Rs m315,7845,154 6,127.3%  
Other income Rs m6,232100 6,244.0%   
Total revenues Rs m322,0165,254 6,129.5%   
Gross profit Rs m100,893-766 -13,166.2%  
Depreciation Rs m12,648711 1,778.8%   
Interest Rs m3,9981,503 266.0%   
Profit before tax Rs m90,479-2,881 -3,141.1%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m99-6 -1,742.1%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m12,11617 72,117.3%   
Profit after tax Rs m78,462-1,121 -6,997.4%  
Gross profit margin %31.9-14.9 -214.9%  
Effective tax rate %13.4-0.6 -2,295.9%   
Net profit margin %24.8-21.8 -114.2%  
BALANCE SHEET DATA
Current assets Rs m329,5373,810 8,648.8%   
Current liabilities Rs m178,8708,365 2,138.2%   
Net working cap to sales %47.7-88.4 -54.0%  
Current ratio x1.80.5 404.5%  
Inventory Days Days79156 50.7%  
Debtors Days Days8367 123.8%  
Net fixed assets Rs m204,76614,480 1,414.1%   
Share capital Rs m2,39961 3,914.0%   
"Free" reserves Rs m363,997903 40,305.3%   
Net worth Rs m366,3975,127 7,146.1%   
Long term debt Rs m14,3615,832 246.3%   
Total assets Rs m614,10219,433 3,160.0%  
Interest coverage x23.6-0.9 -2,578.4%   
Debt to equity ratio x01.1 3.4%  
Sales to assets ratio x0.50.3 193.9%   
Return on assets %13.42.0 683.6%  
Return on equity %21.4-21.9 -97.9%  
Return on capital %24.83.6 683.1%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m44,1181,539 2,866.3%   
Fx outflow Rs m24,484942 2,599.2%   
Net fx Rs m19,634597 3,287.7%   
CASH FLOW
From Operations Rs m70,822599 11,819.4%  
From Investments Rs m-42,216-438 9,640.6%  
From Financial Activity Rs m-22,854-303 7,552.5%  
Net Cashflow Rs m6,107-141 -4,321.8%  

Share Holding

Indian Promoters % 63.7 74.5 85.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.6 855.0%  
FIIs % 23.0 1.3 1,769.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 23.6 35.2%  
Shareholders   133,026 10,259 1,296.7%  
Pledged promoter(s) holding % 0.5 35.1 1.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   AUROBINDO PHARMA  DR. REDDYS LAB  GSK PHARMA  FULFORD INDIA  MERCK LTD  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Volatile; IT Stocks Lead Gains(01:30 pm)

After opening the day flat, share markets in India witnessed choppy trading activity and are presently trading above the dotted line.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Feb 20, 2018 03:35 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS